Genesis Research and Development, which in July abandoned plans to merge with an unlisted Australian company, had its shares halted from trading pending an announcement.
The company suspended operations in May 2010 and laid off its entire staff.
In July this year it placed 9.1 million shares, which it said gave it enough funds to remain listed while it considers further investments.
The shares last traded at 1.8 cents, valuing the company at $980,000, and have declined 40% in the past year.
In July, Genesis called off a proposed merger with Australia-based Mariposa Health, an unlisted public pharmaceutical development company.
This article is tagged with the following keywords. Find out more about MyNBR Tags
- Suburban intensification and sprawl outside city boundary - Unitary Plan
- Punakaiki Fund invests in Taranaki software company
- TradeGecko 'doing millions in revenue' as ex-Kiwi startup builds customers from Singapore
- MARKET CLOSE: Stocks drop, A2 Milk falls ahead of legal challenge, Fletcher Building gains
- Unexpected bedfellows emerge in early Unitary Plan reactions
Most listened to
- The Unitary Plan will change the face of Auckland. NBR reporter Sally Lindsay looks at the changes
- Rabobank's newly appointed CEO Daryl Johnson answers seven key questions on this agriculture industry
- In Editor's Insight, Nevil Gibson examines new revelations about downing of Flight MH370
- InternetNZ boss's two problems with TPP legislation
- Germany’s terror and Turkish torture on Foreign Affairs Scope with Nathan Smith